Compare Charles River Laboratories Intl. Inc (CRL) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs NIO Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $229.81 (market cap $11.14B), while NIO Inc. trades at $5.16 (market cap $12.99B). The key difference: NIO Inc. is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| CRL | NIO | |
|---|---|---|
Market Cap | $11.14B | $12.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $7.89 |
52-Week Low | $145.57 | $4.11 |
Enterprise Value | $14.00B | $12.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
NIO trades at $4.93, up 3.14% today, but remains in a bearish technical trend with negative cash flows and persistent losses despite revenue growth to $87.49 billion in 2025. The company beat EPS estimates for three consecutive quarters, and June 2026 deliveries surged 62.9% year-over-year, indicating strong operational momentum. However, net income margin improved to -17.8% in 2025 but remains deep in negative territory, with a high debt load and substantial cash burn from operations.
Outlook is mixed: bullish delivery growth and analyst upgrades (Goldman Sachs to Buy, target $7) contrast with profitability risks and competitive EV market pressures. Investment appeal hinges on margin improvement and sustainable cash flow generation, while key risks include execution challenges, macroeconomic headwinds, and reliance on financing amid negative equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
